COMP <GO>
IMCR vs LYCA // EV/EBITDA & P/E VALUATION
Immunocore Holdings plc (NASDAQ) VS. Lycia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IMCR 1
— LYCA 1
■ METRIC PARITY
LAST: $31.27 (-4.11%) • MKT CAP: $1.61B
valuation
—
LAST: $27.73 (+10.70%) • MKT CAP: $1.44B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. LYCA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMCR | LYCA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.93% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -11.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -8.90% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 29.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.40 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.4 | 82.2 | -35.82 | LYCA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $1.44B | $165.8M | IMCR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMCR REV | LYCA REV | IMCR GROSS % | LYCA GROSS % | IMCR FCF | LYCA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $400.0M | — | 98.0% | — | -$15.1M | — |
| FY 2024 | $310.2M | — | 98.0% | — | $20.9M | — |
| FY 2023 | $249.4M | — | — | — | $2.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
LYCA // BETA —